2025
Elevated initial blood kynurenine is associated with increased odds of post-stroke infection Kynurenine and post-stroke infection
Dylla L, Reisz J, Poisson S, Herson P, Sansing L, Monte A. Elevated initial blood kynurenine is associated with increased odds of post-stroke infection Kynurenine and post-stroke infection. Journal Of Stroke And Cerebrovascular Diseases 2025, 34: 108268. PMID: 40015349, PMCID: PMC11970113, DOI: 10.1016/j.jstrokecerebrovasdis.2025.108268.Peer-Reviewed Original ResearchConceptsPost-stroke infectionsAssociated with increased oddsTryptophan metabolitesHistory of diabetes mellitusEnd stage renal diseaseNIH Stroke Scale scoreConcentrations of kynurenineAcute ischemic stroke patientsMultivariate logistic regressionStage renal diseaseStroke Scale scoreCirculating kynurenineIschemic stroke onsetIschemic stroke patientsKynurenine concentrationsConcentrations of tryptophanEmergency department admissionsKynurenic acidDiabetes mellitusMortality of ischemic strokeRenal diseaseTryptophan metabolismOdds ratioQuinolinic acidImmune response
2023
Inactivation of Invs/Nphp2 in renal epithelial cells drives infantile nephronophthisis like phenotypes in mouse
Li Y, Xu W, Makova S, Brueckner M, Sun Z. Inactivation of Invs/Nphp2 in renal epithelial cells drives infantile nephronophthisis like phenotypes in mouse. ELife 2023, 12: e82395. PMID: 36920028, PMCID: PMC10154023, DOI: 10.7554/elife.82395.Peer-Reviewed Original ResearchConceptsFlox/Valproic acidRenal fibrosisCyst formationEnd-stage renal diseaseMutant miceHistone deacetylase inhibitor valproic acidKidney function declineStage renal diseaseCell proliferationInhibitor valproic acidEpithelial-stromal crosstalkKnockout mouse modelRenal cyst formationCyst burdenRenal diseaseFunction declineInterstitial fibrosisDisease progressionStromal fibrosisTargeted therapyInfantile nephronophthisisMouse modelMyofibroblast activationRenal epithelial cells
2022
Transurethral resection of posterior urethral valves
Arlen A. Transurethral resection of posterior urethral valves. Urology Video Journal 2022, 15: 100165. DOI: 10.1016/j.urolvj.2022.100165.Peer-Reviewed Original ResearchPosterior urethral valvesUrethral valvesVesicoureteral refluxLower urinary tract obstructionBladder neck hypertrophyBladder wall thickeningUpper tract dilationStage renal diseaseUrinary tract obstructionFetal development resultsTract obstructionRenal diseaseTransurethral resectionDetrusor hypertrophyTract dilationPosterior urethraCommon causeWall thickeningMost valvesHypertrophyDilationValveResectionUrethraObstructionRENALASE: DISCOVERY, BIOLOGY, AND THERAPEUTIC APPLICATIONS.
Desir GV. RENALASE: DISCOVERY, BIOLOGY, AND THERAPEUTIC APPLICATIONS. Transactions Of The American Clinical And Climatological Association 2022, 132: 117-125. PMID: 36196172, PMCID: PMC9480547.Peer-Reviewed Original ResearchConceptsChronic kidney diseaseStage renal diseaseCardiovascular complicationsOrgan survivalRenal diseaseAcute injuryKidney diseaseChronic injurySignificant burdenRenalaseStressful stimuliPeptide agonistsNicotinamide adenine dinucleotideMitochondrial functionInjuryEnergy metabolismDiseaseTherapeutic applicationsAdenine dinucleotideCellsComplicationsPathophysiologyAgonistsKidneyPancreas
2021
Delays in antibiotic redosing: Association with inpatient mortality and risk factors for delay
Kemmler CB, Sangal RB, Rothenberg C, Li SX, Shofer FS, Abella BS, Venkatesh AK, Foster SD. Delays in antibiotic redosing: Association with inpatient mortality and risk factors for delay. The American Journal Of Emergency Medicine 2021, 46: 63-69. PMID: 33735698, DOI: 10.1016/j.ajem.2021.02.058.Peer-Reviewed Original ResearchConceptsSecond dose administrationEmergency departmentDose administrationRisk factorsEmergency Severity IndexHospital mortalityFirst doseSecond doseED boardingAntibiotic dosesEnd-stage renal diseaseExtremes of weightHigh acuity presentationsRetrospective cohort studyStage renal diseaseWorse clinical outcomesSerious bacterial infectionsOdds of delayEarly hospital courseSingle healthcare systemAntibiotic redosingDosing intervalHospital courseCohort studyInpatient mortality
2020
Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure
Mezzacappa C, Ravindra NG, Caraballo C, Chouairi F, Miller PE, Clarke JD, Gruen J, Mori M, McCullough M, Mullan C, Geirsson A, Rogers JG, Anwer M, Desai N, Ahmad T. Clinical implications of differences between real world and clinical trial usage of left ventricular assist devices for end stage heart failure. PLOS ONE 2020, 15: e0242928. PMID: 33270648, PMCID: PMC7714148, DOI: 10.1371/journal.pone.0242928.Peer-Reviewed Original ResearchConceptsClinical trialsVentricular assist deviceExclusion criteriaLVAD recipientsAssist deviceReal-world settingClinical implicationsClinical trial exclusion criteriaHeart failure clinical trialsEnd-stage renal diseaseEnd-stage heart failureReal-world registryRetrospective cohort studyLandmark clinical trialsStage renal diseaseTrial exclusion criteriaRisk of deathStage heart failureRespiratory failureCohort studyPatient characteristicsHeart failurePatient factorsRenal diseaseClinical outcomes
2019
Actinomyces neuii: a case report of a rare cause of acute infective endocarditis and literature review
Yang WT, Grant M. Actinomyces neuii: a case report of a rare cause of acute infective endocarditis and literature review. BMC Infectious Diseases 2019, 19: 511. PMID: 31182045, PMCID: PMC6558687, DOI: 10.1186/s12879-019-4149-2.Peer-Reviewed Case Reports and Technical NotesConceptsInfective endocarditisActinomyces sppEnd-stage renal diseaseBilateral cerebral infarctsOral antibiotic therapyAcute infective endocarditisStage renal diseaseVulnerable patient populationBackgroundInfective endocarditisSeptic emboliValvular surgeryAcute presentationCerebral infarctsCase presentationAFacial droopAntibiotic therapyRenal diseaseRare causePatient populationCase reportClassic presentationConclusionsThis caseEndovascular infectionBlood culturesMonoclonal gammopathy
2018
Polycystin-1, the product of the polycystic kidney disease gene PKD1, is post-translationally modified by palmitoylation
Roy K, Marin EP. Polycystin-1, the product of the polycystic kidney disease gene PKD1, is post-translationally modified by palmitoylation. Molecular Biology Reports 2018, 45: 1515-1521. PMID: 30073588, DOI: 10.1007/s11033-018-4224-6.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseProteins polycystin-1End-stage renal diseasePossible pharmacologic targetsStage renal diseasePossible modifiable factorsRate of progressionDominant polycystic kidney diseaseExpression levelsPolycystic kidney diseaseRenal diseaseKidney diseaseModifiable factorsCommon causePharmacologic targetPolycystin-1Carboxyl-terminal fragmentKidney cystsPC1 expressionPotential causesDiseaseDistinct mutationsPost-translational modificationsMultiple complementary approachesGenes PKD1High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions
MCCOY R, HOUTEN H, LIPSKA K, SHAH N. High-Risk Medication Use to Achieve Tight Glycemic Control among U.S. Adults with Serious Chronic Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-1652-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseChronic obstructive pulmonary diseaseMajority of patientsHeart failureMyocardial infarctionSerious comorbiditiesGlycemic controlCerebrovascular diseaseChronic conditionsHigh-risk medication usePlurality of patientsProportion of patientsObstructive pulmonary diseaseStage renal diseaseUse of insulinOptumLabs Data WarehouseTight glycemic controlHigh-risk drugsSerious chronic conditionsMedicare Advantage beneficiariesGlycemic targetsUrinary incontinenceMedication usePeripheral neuropathyHospitalization and Emergency Department Visits for Severe Hypoglycemia among U.S. Adults with Diabetes and Serious Comorbid Conditions
MCCOY R, VAN HOUTEN H, LIPSKA K, SHAH N. Hospitalization and Emergency Department Visits for Severe Hypoglycemia among U.S. Adults with Diabetes and Serious Comorbid Conditions. Diabetes 2018, 67 DOI: 10.2337/db18-381-p.Peer-Reviewed Original ResearchEnd-stage renal diseaseChronic kidney diseaseSevere hypoglycemiaChronic conditionsChronic obstructive pulmonary diseaseRate of hospitalSerious comorbid conditionsGlucose-lowering therapyNumber of comorbiditiesEmergency department visitsObstructive pulmonary diseaseStage renal diseaseEmergency department careRisk of hypoglycemiaLimited life expectancyOptumLabs Data WarehouseSpecific chronic conditionsHigh clinical complexityPrior hypoglycemiaDiabetes medicationsMultiple comorbiditiesGlycemic targetsHypoglycemia ratesUrinary incontinenceDepartment visits
2017
Physiology of Peritoneal Dialysis
Moreno A, Sarav M. Physiology of Peritoneal Dialysis. 2017, 7-15. DOI: 10.1007/978-3-319-52821-2_2.Peer-Reviewed Original Research
2015
Early outcomes after elective colorectal surgery in end stage renal disease (ESRD) vs non-ESRD Patients
Arhuidese I, Malas M, Obeid T, Qazi U, Ahuja N, Efron J. Early outcomes after elective colorectal surgery in end stage renal disease (ESRD) vs non-ESRD Patients. Journal Of The American College Of Surgeons 2015, 221: e59. DOI: 10.1016/j.jamcollsurg.2015.08.052.Peer-Reviewed Original ResearchIgG4‐related tubulointerstitial nephritis: A prospective analysis
Nada R, Ramachandran R, Kumar A, Rathi M, Rawat A, Joshi K, Kohli H, Gupta K. IgG4‐related tubulointerstitial nephritis: A prospective analysis. International Journal Of Rheumatic Diseases 2015, 19: 721-729. PMID: 26355389, DOI: 10.1111/1756-185x.12675.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAutoimmune DiseasesBiomarkersBiopsyDisease ProgressionFemaleFollow-Up StudiesGlomerulonephritis, MembranousHumansImmunoglobulin GImmunohistochemistryImmunosuppressive AgentsIndiaKidneyKidney Failure, ChronicMaleMiddle AgedNephritis, InterstitialProspective StudiesProteinuriaRemission InductionTime FactorsTreatment OutcomeYoung AdultConceptsEnd stage renal diseaseStage renal diseaseRenal diseaseFollow-upSteroid therapyRenal dysfunctionExtra-renal organ involvementIgG4-related systemic diseaseSerum IgG4 levelsProgressive chronic kidney diseaseEnd-stage renal diseaseExtra-renal manifestationsFocal renal massesProgressive renal failurePattern CTubulo-interstitial nephritisProspective Follow-upChronic kidney diseaseImmunosuppressive therapyAggressive courseIgG4 levelsHistological diagnosisRenal massesSerum creatinineOrgan involvementComparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome
Castano E, Palmer MB, Vigneault C, Luciano R, Wong S, Moeckel G. Comparison of amyloid deposition in human kidney biopsies as predictor of poor patient outcome. BMC Nephrology 2015, 16: 64. PMID: 25924613, PMCID: PMC4424547, DOI: 10.1186/s12882-015-0046-0.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseAmyloid depositionPatient outcomesAmyloid depositsBiopsy-proven renal amyloidosisHistological localizationHigher serum creatinineInterstitial inflammatory infiltrateStage renal diseaseUrine protein levelsGlomerular amyloid depositionGlomerular amyloid depositsPoor patient outcomesGlomerular capillary loopsHuman kidney biopsiesDifferent study groupsStudent's t-testGlomerular amyloidosisOverall survivalSerum creatinineVascular amyloidosisKidney biopsyRenal diseaseInflammatory infiltrateClinical parameters
2013
Outcomes of Peritonitis in Children on Peritoneal Dialysis: A 25-Year Experience at Severance Hospital
Lee K, Park J, Kim J, Lee J, Kim P, Shin J. Outcomes of Peritonitis in Children on Peritoneal Dialysis: A 25-Year Experience at Severance Hospital. Yonsei Medical Journal 2013, 54: 983-989. PMID: 23709435, PMCID: PMC3663235, DOI: 10.3349/ymj.2013.54.4.983.Peer-Reviewed Original ResearchConceptsContinuous ambulatory PDOutcome of peritonitisAutomated PDPeritonitis episodesOutcomes of peritoneal dialysis (PD)-associated peritonitisSeverance HospitalPD patientsPeritoneal dialysis (PD)-associated peritonitisIncidence of PD peritonitisClinical outcomes of peritonitisCommencement of PDEpisodes of peritonitisIncidence of peritonitisPediatric PD patientsInitiation of PDEnd stage renal diseaseOutcomes of PDStage renal diseasePD peritonitisAntibiotic regimensPermanent hemodialysisAntibiotic therapyPeritoneal dialysisClinical outcomesRenal diseaseSubclavian Aneurysm Presenting with Massive Hemoptysis: A Case Report and Review of the Literature
Brown HA, Aruny JE, Elefteriades JA, Sumpio BE. Subclavian Aneurysm Presenting with Massive Hemoptysis: A Case Report and Review of the Literature. International Journal Of Angiology 2013, 22: 069-074. PMID: 24436588, PMCID: PMC3699228, DOI: 10.1055/s-0033-1333862.Peer-Reviewed Original ResearchSubclavian aneurysmMassive hemoptysisMethicillin-resistant Staphylococcus aureus endocarditisAmplatzer II vascular plugEnd-stage renal diseaseLeft upper lobe bronchusCoronary artery bypassInternal mammary arterySubclavian artery aneurysmArtery bypass graftBright red bloodStage renal diseaseUpper lobe bronchusPast medical historyStaphylococcus aureus endocarditisChallenging clinical problemEndocardial pacing leadsArtery bypassMammary arteryCoronary angiographyLobe bronchusOpen repairRenal diseaseArtery aneurysmBypass graft
2011
Health Utilities for Children and Adults With Type 1 Diabetes
Lee JM, Rhee K, O'Grady MJ, Basu A, Winn A, John P, Meltzer DO, Kollman C, Laffel LM, Lawrence JM, Tamborlane WV, Wysocki T, Xing D, Huang ES. Health Utilities for Children and Adults With Type 1 Diabetes. Medical Care 2011, 49: 924-931. PMID: 21544001, PMCID: PMC3210197, DOI: 10.1097/mlr.0b013e318216592c.Peer-Reviewed Original ResearchConceptsParent-proxy reportsType 1 diabetesHealth utilityProxy reportsEnd-stage renal diseaseEnd-stage complicationsStage renal diseaseChild Self-ReportSelf-ReportSignificant differencesRenal diseaseAdult Self-ReportHigher overall QoLOverall QOLCurrent QoLOverall qualityHigher QoLQoLFunction of ageType 1DiabetesAdultsComplicationsMethods of assessmentChildren
2009
HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin
Hakim W, Sheikh S, Inayat I, Caldwell C, Smith D, Lorber M, Friedman A, Jain D, Bia M, Formica R, Mehal W. HCV Response in Patients With End Stage Renal Disease Treated With Combination Pegylated Interferon α-2a and Ribavirin. Journal Of Clinical Gastroenterology 2009, 43: 477-481. PMID: 19142165, PMCID: PMC3715868, DOI: 10.1097/mcg.0b013e318180803a.Peer-Reviewed Original ResearchConceptsEnd-stage renal diseaseHepatitis C virusCombination therapyRenal diseasePosttreatment rateSide effectsSerious adverse side effectsDose of ribavirinNon-ESRD patientsSafe therapeutic optionEarly virologic responseProspective observational studyMonths of treatmentStage renal diseaseCases of anemiaInitial response rateLength of treatmentInterferon α-2aAdverse side effectsPO weeklyVirologic responseESRD patientsHCV infectionESRD populationHCV response
2006
The Anti‐platelet Effect of Aspirin in Patients with End Stage Renal Disease
Faheem O, Shah A, Haider J, Schumacher J, Liang T, Azrin M, Bellumkonda L, Walsh S, Kaplan A, Liang B. The Anti‐platelet Effect of Aspirin in Patients with End Stage Renal Disease. The FASEB Journal 2006, 20: a1139-a1139. DOI: 10.1096/fasebj.20.5.a1139.Peer-Reviewed Original ResearchAnti-platelet effectsRenal failurePlatelet aggregationControl patientsArachidonic acidEnd-stage renal diseaseAnti-platelet responseGreater platelet aggregationStage renal diseaseAgonist-induced platelet aggregationRenal failure patientsASA ingestionASA resistanceAspirin resistanceVascular eventsFailure patientsRenal diseaseControl subjectsPatientsPlatelet agonistsWhole bloodAgonistsASAVariable responseSubjects
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply